Chardan Capital Maintains Buy on Intellia Therapeutics, Lowers Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has maintained a Buy rating on Intellia Therapeutics but lowered the price target from $94 to $88.

October 24, 2024 | 9:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chardan Capital has maintained a Buy rating on Intellia Therapeutics but lowered the price target from $94 to $88.
The maintenance of a Buy rating suggests continued confidence in Intellia's prospects, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100